A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
about
Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateEnhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.MEK inhibitors in oncology: a patent review (2015-Present).A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.Recent advances in the biology and therapy of medullary thyroid carcinoma.Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
P2860
Q33887664-6EB35BE7-A1AF-4A43-9258-A894A3B52FFAQ37421296-C47B35EA-42AB-4520-937B-CF020C8C1FF9Q39359514-CFAE84BE-2D3A-4F6B-A191-F16910D0303FQ47130538-5AFB3822-435C-4C9C-AB84-57FA53CD1EB5Q47836520-A11DCCA8-F833-4B5B-9028-201F733F31A3Q48246978-971205CD-6879-4BBF-B4C3-54968F19473DQ52607328-B589C464-A115-4C53-83F0-2DE64F90E070
P2860
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A phase Ib dose-escalation stu ...... ts with advanced solid tumors.
@en
type
label
A phase Ib dose-escalation stu ...... ts with advanced solid tumors.
@en
prefLabel
A phase Ib dose-escalation stu ...... ts with advanced solid tumors.
@en
P2093
P2860
P1476
A phase Ib dose-escalation stu ...... nts with advanced solid tumors
@en
P2093
A R Abdul Razak
G Del Conte
H A Burris
J E Grilley-Olson
J R Infante
P2860
P2888
P304
P356
10.1007/S10637-016-0377-0
P577
2016-07-23T00:00:00Z
P6179
1040010442